Impact Biomedical (IBO) Other Operating Expenses (2022 - 2026)

Impact Biomedical (IBO) has reported Other Operating Expenses for 5 consecutive years, with $462000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses fell 44.8% year-over-year to $462000.0; the trailing twelve-month figure through Jun 2026 stood at $1.7 million (down 93.73% YoY), and the FY2024 full-year result was $27.4 million, up 1390.48% from the prior year.
• Other Operating Expenses retreated to $462000.0 in Q2 2026 per IBO's latest filing, from $630000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $25.8 million in Q4 2024 and bottomed at $252000.0 in Q4 2023.
• Historically, Other Operating Expenses has averaged $2.1 million across 5 years, with a median of $557000.0 in 2023.
• The widest YoY moves for Other Operating Expenses: up 10133.73% in 2024, down 47.67% in 2024.
• Over 5 years, Other Operating Expenses stood at $443000.0 in 2022, then plunged by 43.12% to $252000.0 in 2023, then jumped by 10133.73% to $25.8 million in 2024, then slumped by 97.47% to $652000.0 in 2025, then retreated by 29.14% to $462000.0 in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $462000.0, $630000.0, and $652000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.